The US COVID-19 response was the topic of the Senate Health, Education, Labor and Pensions Committee’s 20 July hearing, but members could not resist asking about the controversial Alzheimer’s drug Aduhelm (aducanumab-avwa) as well.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?